| Original language | English (US) |
|---|---|
| Pages (from-to) | 1187-1189 |
| Number of pages | 3 |
| Journal | JACC: Clinical Electrophysiology |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2023 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JACC: Clinical Electrophysiology, Vol. 9, No. 7, 07.2023, p. 1187-1189.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - 1-Year Outcomes of a Leadless Ventricular Pacemaker
T2 - The LEADLESS II (Phase 2) Trial
AU - LEADLESS II Investigators
AU - Reddy, Vivek Y.
AU - Exner, Derek V.
AU - Doshi, Rahul
AU - Tomassoni, Gery
AU - Bunch, T. Jared
AU - Friedman, Paul
AU - Estes, N. A.Mark
AU - Neužil, Petr
AU - de la Concha, Joaquin Fernandez
AU - Cantillon, Daniel J.
N1 - Funding Information: Abbott provided funding for the LEADLESS II (phase 2) trial. Dr Reddy is a consultant for Abbott; also, unrelated to this paper, he has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Apama Medical-Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT / AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Farapulse-Boston Scientific, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, and Valcare; unrelated to this work, has served as a consultant for Abbott, AtriAN, Biosense Webster, BioTel Heart, Biotronik, Boston Scientific, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Philips, and Pulse Biosciences; and has equity in Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizaramed. Dr Exner is a consultant for and receives research support from Abbott. Dr Doshi is a consultant for Abbott. Dr Tomassoni is a consultant and speaker for Abbott and Boston Scientific. Dr Bunch is a consultant for Abbott; and has received research grants from Altathera and Boston Scientific. Dr Friedman serves as an advisory board member for Medtronic, Boston Scientific, and Abbott. Dr Estes is a consultant for Abbott, Medtronic, and Boston Scientific. Dr Fernandez de la Concha is a consultant for Abbott, Medtronic, and Biotronik. Dr Cantillon is a consultant for Abbott and Boston Scientific. Dr Neužil has reported that he has no relationships relevant to the contents of this paper to disclose.
PY - 2023/7
Y1 - 2023/7
UR - http://www.scopus.com/inward/record.url?scp=85157969215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85157969215&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2023.01.031
DO - 10.1016/j.jacep.2023.01.031
M3 - Letter
C2 - 36951813
AN - SCOPUS:85157969215
SN - 2405-500X
VL - 9
SP - 1187
EP - 1189
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 7
ER -